Catalyst Patent-Cliff Exposure & CMS Drug Spending Portfolio
Catalyst (US): 3 reconciled FDA prescription therapies (42.7% 2025 to 2030 cliff risk), $412.1M 2024 CMS Part D & Medicaid spend, and 22 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 42.7% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $412.1M |
| 2024 Medicare Part D Spend | $254.2M |
| 2024 Medicaid Spend | $157.9M |
| California HCAI SB 17 Filings | 22 WAC filings (max 21.4% 2-yr change) |